News Daily News Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER Michael O'Riordan December 12, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Daily News Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions L.A. McKeown September 22, 2025
News Conference News ESC 2025 NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure Michael O'Riordan September 04, 2025
News Conference News ESC 2025 High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors Caitlin E. Cox August 29, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025
News Daily News Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis Michael O'Riordan July 03, 2025
News Daily News Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board Michael O'Riordan June 25, 2025
News Daily News Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION Michael O'Riordan June 04, 2025
News Conference News EuroPCR 2025 Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI L.A. McKeown May 22, 2025
News Daily News Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE Caitlin E. Cox April 23, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News ACC 2025 STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients L.A. McKeown March 29, 2025
News Daily News ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients Michael O'Riordan March 26, 2025
News Daily News Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA Michael O'Riordan February 24, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025